What happened
Chai, a biotech firm supported by OpenAI, secured £130 million in Series B funding, achieving a £1.3 billion valuation. This investment will advance the development and refinement of its AI-driven foundation models, which are designed to predict molecular interactions for drug discovery and therapeutic repurposing. The models aim to accelerate the identification of promising drug candidates and potential treatments.
Why it matters
The substantial investment in AI foundation models for drug discovery introduces a significant operational dependency on the performance and explainability of these predictive systems. This raises due diligence requirements for R&D and compliance teams regarding the validation of AI-derived molecular interaction predictions and the governance of associated data inputs and outputs. It also increases exposure to potential model biases or inaccuracies impacting therapeutic development pathways.
